| Richard Keith Hacker, MD | |
|
412 Como Rd, Lake Como, PA 18437-1020 | |
| (570) 798-2828 | |
| (570) 798-2636 |
| Full Name | Richard Keith Hacker |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 40 Years |
| Location | 412 Como Rd, Lake Como, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013959675 | NPI | - | NPPES |
| 1018670380007 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD4287949 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Personal Home Healthcare And Hospice | Dunmore, PA | Home health agency |
| Revolutionary Home Health Inc | Olyphant, PA | Home health agency |
| Wayne Memorial Hospital | Honesdale, PA | Hospital |
| Geisinger-community Medical Center | Scranton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wayne Memorial Community Health Centers | 3072598937 | 18 |
News Archive
Individuals from certain areas of the United States are more likely to get screened for colorectal cancer than those from other areas, particularly when comparing non-whites living in different parts of the country. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Additional research is needed to better understand how colorectal cancer screening disparities develop in some regions and not in others.
Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).
Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.
› Verified 2 days ago
| Entity Name | Wayne Memorial Community Health Centers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952395121 PECOS PAC ID: 3072598937 Enrollment ID: O20040623001109 |
News Archive
Individuals from certain areas of the United States are more likely to get screened for colorectal cancer than those from other areas, particularly when comparing non-whites living in different parts of the country. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Additional research is needed to better understand how colorectal cancer screening disparities develop in some regions and not in others.
Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).
Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.
› Verified 2 days ago
| Entity Name | Brookville Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063560852 PECOS PAC ID: 3072579598 Enrollment ID: O20050428000025 |
News Archive
Individuals from certain areas of the United States are more likely to get screened for colorectal cancer than those from other areas, particularly when comparing non-whites living in different parts of the country. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Additional research is needed to better understand how colorectal cancer screening disparities develop in some regions and not in others.
Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).
Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.
› Verified 2 days ago
| Entity Name | Pennsylvania Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497059802 PECOS PAC ID: 1153507025 Enrollment ID: O20110511000343 |
News Archive
Individuals from certain areas of the United States are more likely to get screened for colorectal cancer than those from other areas, particularly when comparing non-whites living in different parts of the country. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Additional research is needed to better understand how colorectal cancer screening disparities develop in some regions and not in others.
Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).
Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Keith Hacker, MD 601 Park St, Honesdale, PA 18431-1445 Ph: (570) 253-8226 | Richard Keith Hacker, MD 412 Como Rd, Lake Como, PA 18437-1020 Ph: (570) 798-2828 |
News Archive
Individuals from certain areas of the United States are more likely to get screened for colorectal cancer than those from other areas, particularly when comparing non-whites living in different parts of the country. That is the conclusion of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Additional research is needed to better understand how colorectal cancer screening disparities develop in some regions and not in others.
Wyeth Pharmaceuticals has announced that the U.S. Food and Drug Administration has granted a new "fast track" designation for temsirolimus (CCI-779), an investigational mTOR kinase inhibitor, in the first-line treatment of poor-prognosis patients with advanced renal cell carcinoma (RCC).
Quadrant Biosciences, Inc., an emerging life science company based in Syracuse, N.Y., today announced its collaboration with the Autism Speaks® Autism Treatment Network and its university research partners on research into the treatment of autism spectrum disorder.
A synthetic mixture of intestinal bacteria could one day replace stool transplants as a treatment for Clostridium difficile (C. difficile). C. difficile is a toxin-producing bacteria that can overpopulate the colon when antibiotics eradicate other, naturally protective bacteria living there.
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.
› Verified 2 days ago